定量177Lu-DOTATATE SPECT/CT可预测中肠神经内分泌肿瘤6个月PRRT形态学反应:一项先导研究
该先导研究纳入12例进展性转移性小肠神经内分泌肿瘤患者,在接受177Lu-DOTATATE肽受体放射性核素治疗第一周期和第二周期后行定量治疗后闪烁显像SPECT/CT,测量摄取最高病灶的SUVmax并计算∆SUVmax,分析其与6个月RECIST百分比的相关性,发现两者强相关(回归公式:6个月RECIST = -0.05 + 0.36 × ∆SUVmax,p < 0.001),∆MTV无预测价值,结论需在更大样本中确认。
要点
- 12例进展性转移性小肠神经内分泌肿瘤患者中,仅1例6个月时达部分缓解,其余为疾病稳定。
- 6个月RECIST百分比与∆SUVmax强相关,回归公式为6个月RECIST = -0.05 + 0.36 × ∆SUVmax(p < 0.001)。
- ∆MTV对反应无预测价值;定量影像或可在第二周期即预测6个月反应,但需更大样本确认。
核心结论
- 本研究报告小肠神经内分泌肿瘤患者治疗后闪烁显像∆SUVmax与6个月RECIST百分比之间存在显著关联。
- 定量影像或可在第二周期即预测177Lu-DOTATATE的6个月反应。
- 这些结果需在更大样本中确认。
研究设计与样本
- 先导研究,纳入转诊至本中心接受177Lu-DOTATATE治疗的连续12例进展性转移性小肠神经内分泌肿瘤患者。
- 在第一周期和第二周期治疗后闪烁显像SPECT/CT上测量摄取最高病灶的SUVmax并计算∆SUVmax。
- 采用线性回归分析∆SUVmax与6个月RECIST百分比的关系,并研究肿瘤代谢体积(MTV)相对变化及临床参数。
主要发现
- 12例患者中1例在6个月时达部分缓解,其余为疾病稳定。
- 线性回归显示6个月RECIST百分比与∆SUVmax强相关,回归公式为6个月RECIST = -0.05 + 0.36 × ∆SUVmax(p < 0.001)。
- ∆MTV对反应无预测价值。
关键数值与推荐
- 疗效评估采用RECIST标准,于治疗结束后数月进行。
- 6个月RECIST百分比与∆SUVmax的回归公式为6个月RECIST = -0.05 + 0.36 × ∆SUVmax(p < 0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文指出这些结果需在更大样本中确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: peptide receptor radionuclide therapy with 177Lu-DOTATATE has become an established second-line treatment for patients with advanced small intestine neuroendocrine tumors (siNET). Treatment efficacy is assessed several months after the end of treatment and is based on RECIST criteria. Post-therapy scintigraphy (PTS) can be performed after each cycle, but its value in early response assessment is debated particularly given the lack of quantification available in clinical routine. New quantification modules are now available, enabling automatic SUV calculation. The main goal of this study is to assess the value of the evolution of SUV between the first (C1) and the second (C2) cycle on quantitative PTS in predicting response to treatment. All patients with siNET referred to our center for treatment with 177Lu-DOTATATE were included. The SUVmax of the lesion with the greatest uptake was measured on PTS SPECT/CT at C1 and C2. ∆SUVmax was calculated. Linear regression between ∆SUVmax and 6-month RECIST percentage was used. Relative changes in tumor metabolic volume (MTV) were also studied along with clinical parameters. RESULTS: twelve consecutive patients with progressive metastatic siNET were included. One patient showed partial response at 6 months, the other were considered as stable disease. Linear regression showed that 6-month RECIST percentage and ∆SUVmax were strongly correlated with the following regression formula: 6-month RECIST = -0.05 + 0.36 x ∆SUVmax (p < 0.001). ∆MTV was not predictive of response. CONCLUSION: we report a significant link between PTS ∆SUVmax and 6-month RECIST percentage in patients with siNET. Quantitative imaging would thus enable the prediction of 6-month response of 177Lu-DOTATATE as early as C2. These results need to be confirmed on a larger population.
引用
- Megherbi I, Hoog C, Perrier M, et al. Quantitative 177Lu-DOTATATE SPECT/CT is predictive of 6-month PRRT morphological response in midgut neuroendocrine tumors: a pilot study. EJNMMI Res. 2025. PMID: 40329099. doi:10.1186/s13550-025-01250-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。